These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 38517776)
1. A novel disulfidptosis-related prognostic gene signature and experimental validation identify ACTN4 as a novel therapeutic target in lung adenocarcinoma. Xie K; Wang B; Pang P; Li G; Yang Q; Fang C; Jiang W; Feng Y; Ma H Cancer Biomark; 2024 Feb; ():. PubMed ID: 38517776 [TBL] [Abstract][Full Text] [Related]
2. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma. Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L Aging (Albany NY); 2024 Jun; 16(11):9972-9989. PubMed ID: 38862217 [TBL] [Abstract][Full Text] [Related]
3. Molecular map of disulfidptosis-related genes in lung adenocarcinoma: the perspective toward immune microenvironment and prognosis. Zhao F; Su L; Wang X; Luan J; Zhang X; Li Y; Li S; Hu L Clin Epigenetics; 2024 Feb; 16(1):26. PubMed ID: 38342890 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic and prognostic effect of disulfidptosis-related genes in lung adenocarcinoma. Li C; Sun C; Li Y; Dong L; Wang X; Li R; Su J; Cao Q; Xin S Heliyon; 2024 Jul; 10(13):e33764. PubMed ID: 39050421 [TBL] [Abstract][Full Text] [Related]
5. Identification of a disulfidptosis-related genes signature for prognostic implication in lung adenocarcinoma. Huang J; Zhang J; Zhang F; Lu S; Guo S; Shi R; Zhai Y; Gao Y; Tao X; Jin Z; You L; Wu J Comput Biol Med; 2023 Oct; 165():107402. PubMed ID: 37657358 [TBL] [Abstract][Full Text] [Related]
6. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma. Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243 [TBL] [Abstract][Full Text] [Related]
7. The expression and prognostic value of disulfidptosis progress in lung adenocarcinoma. Ni L; Yang H; Wu X; Zhou K; Wang S Aging (Albany NY); 2023 Aug; 15(15):7741-7759. PubMed ID: 37552140 [TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a disulfidptosis-related genes prognostic signature in lung adenocarcinoma. Zhang Y; Sun J; Li M; Hou L; Wang Z; Dong H; Xu W; Jiang R; Geng Y; Guan C; Zhu Z; Wang H; Gong Q; Zhang G Heliyon; 2024 Jan; 10(1):e23502. PubMed ID: 38223725 [TBL] [Abstract][Full Text] [Related]
9. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma. Zhang HB; Pan JY; Zhu T Front Pharmacol; 2023; 14():1254119. PubMed ID: 37822882 [No Abstract] [Full Text] [Related]
10. Construction of lncRNA prognostic model related to disulfidptosis in lung adenocarcinoma. Zhang L; Wang S; Wang L Heliyon; 2024 Aug; 10(15):e35657. PubMed ID: 39170273 [TBL] [Abstract][Full Text] [Related]
11. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns. Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675 [TBL] [Abstract][Full Text] [Related]
12. Deciphering disulfidptosis: Uncovering a lncRNA-based signature for prognostic assessment, personalized immunotherapy, and therapeutic agent selection in lung adenocarcinoma patients. Ma C; Zhao H; Sun Y; Ding W; Wang H; Li Y; Gu Z Cell Signal; 2024 May; 117():111105. PubMed ID: 38369264 [TBL] [Abstract][Full Text] [Related]
13. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer. Xiong Y; Kong X; Mei H; Wang J; Zhou S Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783 [TBL] [Abstract][Full Text] [Related]
14. Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation. Wang Y; Xu Y; Liu C; Yuan C; Zhang Y Front Immunol; 2023; 14():1233260. PubMed ID: 37799714 [TBL] [Abstract][Full Text] [Related]
15. Construction and validation of a novel ferroptosis-related prognostic signature for lung adenocarcinoma. Yang L; Fan X; Zhou C; Wang Z; Cui Z; Wu X; Xu Z; Yang J; Zhang X Transl Lung Cancer Res; 2023 Aug; 12(8):1766-1781. PubMed ID: 37691861 [TBL] [Abstract][Full Text] [Related]
16. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay. Liang H; Li Y; Qu Y; Zhang L Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574 [TBL] [Abstract][Full Text] [Related]
17. Disulfidptosis-related gene Zhu J; Ge H; Chen Y; Zhang S; Wu J; Nai W; Min L Transl Cancer Res; 2024 Sep; 13(9):5064-5072. PubMed ID: 39430814 [TBL] [Abstract][Full Text] [Related]
18. A novel pyroptosis-related prognostic signature for lung adenocarcinoma: Identification and multi-angle verification. Wang X; Zhou J; Li Z; Chen X; Wei Q; Chen K; Jiang R Front Genet; 2023; 14():1160915. PubMed ID: 37077542 [No Abstract] [Full Text] [Related]
19. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma. Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y Front Immunol; 2022; 13():950001. PubMed ID: 36091041 [TBL] [Abstract][Full Text] [Related]
20. A more novel and powerful prognostic gene signature of lung adenocarcinoma determined from the immune cell infiltration landscape. Ma C; Li F; He Z; Zhao S Front Surg; 2022; 9():1015263. PubMed ID: 36311939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]